Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT04177810
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemiplimab — DRUG
    Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
  • Plerixafor — DRUG
    Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.

Study Details

The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.

Key Dates

Start date
Nov 16, 2020
Status verified
Feb 2024
Primary completion
Mar 29, 2023
Completion
May 19, 2023

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cemiplimab and Plerixafor
    All participants will receive Cemiplimab and Plerixafor.

Primary Outcome Measure

Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria [ Time Frame: 10 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21231-

Find similar trials in Baltimore, MD

By research site
Sidney Kimmel Comprehensive Cancer Center· Baltimore, MD

Related Studies